Treace Medical Concepts Third Quarter 2026 Earnings Conference Call - TREACE MEDICAL CONCEPTS INC

Explicit Guidance:

• FY2026 Revenue: Narrowed range to $206 million – $210 million (vs. prior $204m–$212m), representing a 3% to 1% decline from FY2025. Assumes a return to revenue growth in Q4 2026 driven by procedure volume increases and the phasing out of unfavorable ASP mix dynamics from 2025 product launches.
• FY2026 Adjusted EBITDA: Updated expectation of a loss in the range of $1 million – $2 million (vs. $3.9 million loss in FY2025), implying >60% improvement.
• Cash Usage: Reiterates expectation for cash usage reduction of approximately 50% for FY2026 compared to FY2025.
• Q4 2026 Outlook: Anticipates seasonally strong performance with revenue growth driven by increased procedure volumes and the transition away from lower-priced product mix headwinds.
• FY2027 Guidance: Management deferred specific financial guidance for FY2027, stating they intend to provide detailed guidance during the Q4 2026 earnings call after observing full-year performance and additional months of new product adoption.

Business-Segment Outlook:

• Bunion Systems: Aiming to expand adoption of three 2025 launch systems (Nanoplasty, Percuplasty, Speed MTP) from the current 45% usage among Lapidus surgeons (up from 40% in Q2) toward full portfolio utilization. Expecting continued "pull-through" of Lapidus products as surgeons adopt new minimally invasive systems.
• Lapidus Technology: Full commercial launch of the Lightning platform (faster procedure/3D control) scheduled for Q1 2027. Continued expansion of the IntelliGuide PSI patient-specific planning platform to address complex and revisional cases.
• Adjacent Procedures (Mid/Hind Foot): Full commercialization of Cartoblaster power rasps and VitaFuse bioactive grafts expected in Q4 2026. Full commercialization of Taylor Plasty system (for bunionettes) expected in Q1 2027.
• TAM Expansion: New 2026 product introductions (SuperBite, HyperPlate XM, VitaFuse, Cartoblaster) expected to expand Total Addressable Market (TAM) by an estimated $700 million total, with the Q3/Q4 2026 suite alone adding $400 million.
• Market Share: Projecting coverage of 80%+ of an average surgeon's reconstructive foot and ankle volumes (up from ~30% previously), leveraging the expanded portfolio to capture higher wallet share.

Market and Competitive Outlook:

• Demand Trends: Double-digit case volume growth observed in Q3 2026; management expects this trend to continue into Q4 2026.
• ASP Dynamics: Anticipates a temporary narrowing of the gap between volume growth and revenue growth as the ASP mix shifts toward lower-priced minimally invasive products initially, balanced by higher ASP opportunities in complex midfoot/rearfoot cases. Long-term strategy aims to grow above historical mid-single-digit market rates.
• Competitive Positioning: Leveraging a diversified portfolio to position Treece Medical as a comprehensive "one-stop shop," reducing reliance on single-product adoption and increasing surgeon dependency on the full ecosystem.
• International Expansion: Identifying international markets as a material opportunity given global surgeon demand, but noting significant execution timelines; no specific targets or timing provided pending further materialization.

Macro / Industry Outlook:

• Procedure Volumes: Management counters broader industry narratives of slowing volumes by citing unique tailwinds from new product launches (e.g., SuperBite entering new procedure types) and the seasonal strength of the bunion market.
• Elective Surgery Environment: Confident in consumer/patient demand for elective foot and ankle procedures heading into the year-end season, driven by the expanded product portfolio.

Strategic Initiatives:

• Product Cadence: Commitment to a "steady cadence" of new product and procedural innovations through 2027 and beyond, launching systems like SuperBite, HyperPlate XM, and Taylor Plasty.
• Sales Force Strategy: No plans for dramatic sales force expansion; strategy focuses on incremental hiring and leveraging variable commission costs to drive efficiency (1.5x cases per rep) across the expanded portfolio.
• Clinical Evidence: Leveraging five-year Align3D prospective study data (showing low recurrence and pain reduction) and other recent multicenter studies to strengthen surgeon adoption and clinical defense against competitors.

Risks and Headwinds to Outlook:

• ASP Mix Shift: Continued transition to lower-priced minimally invasive products may pressure average selling prices and revenue growth in the near term until higher-value complex case penetration increases.
• Execution Risk: Phasing of multiple new product introductions (Taylor Plasty, Lightning, etc.) alongside the busy Q4 bunion season requires careful management to avoid diluting focus on core Lapidus business.
• Stocking Distributor Dynamics: One-time headwinds from lower stocking distributor orders in Q3 2025 (vs. significant orders in Q4 2025) are expected to normalize, but fluctuations in these orders could impact reported revenue trends.
• Regulatory/Market Uncertainty: Standard forward-looking statement risks regarding actual results differing from estimates due to market trends, patient adoption rates, and economic conditions.

Management Tone on the Future:

• Confidence Level: High confidence in the "return to growth" narrative for Q4 2026, describing the shift from Q3 revenue decline to projected Q4 growth as a "huge win" and "meaningful change."
• Strategic Clarity: Tone emphasizes disciplined expense management alongside aggressive product innovation. Management expresses satisfaction with the "stickiness" and reorder rates of new systems and the operational leverage achieved despite revenue declines in prior quarters.
• Guidance Hedges: Management exercised caution in FY2026 guidance by narrowing the range and deferring FY2027 guidance to ensure expectations are "achievable" and reflective of visibility after observing the upcoming busy season and new product performance.

Miscellaneous:

• Cash Position: Cash equivalents and marketable securities totaled $39.8 million as of September 30, 2026, providing a "strong and flexible balance sheet."
• Financial Metrics: Year-to-date cash usage reduced by 53% ($9.7 million) compared to FY2025; Q3 2026 Adjusted EBITDA turned positive at $0.3 million.
• Sales Force Adoption: 3,300 active surgeon customers; goal is deepening penetration where nearly half currently use at least one new system, aiming for 100%+ adoption of the full portfolio among these accounts.